{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:27:43Z","timestamp":1790314063365,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-025-00797-8","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T18:03:02Z","timestamp":1753120982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between fumarate hydratase variant subtypes and the risk of HLRCC-associated renal cell carcinoma: systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Han","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsnur","family":"Rehim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"5","key":"797_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/gim.2016.139","volume":"19","author":"GP Jarvik","year":"2017","unstructured":"Jarvik GP, Evans J. Mastering genomic terminology. Genet Med. 2017;19(5):491\u20132. https:\/\/doi.org\/10.1038\/gim.2016.139.","journal-title":"Genet Med"},{"issue":"8","key":"797_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJM198608213150801","volume":"315","author":"AB Zinn","year":"1986","unstructured":"Zinn AB, Kerr DS, Hoppel CL. Fumarase deficiency: A new cause of mitochondrial encephalomyopathy. N Engl J Med. 1986;315(8):469\u201375. https:\/\/doi.org\/10.1056\/NEJM198608213150801.","journal-title":"N Engl J Med"},{"issue":"6","key":"797_CR3","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1172\/JCI117261","volume":"93","author":"T Bourgeron","year":"1994","unstructured":"Bourgeron T, Chretien D, Poggi-Bach J, et al. Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J Clin Invest. 1994;93(6):2514\u20138. https:\/\/doi.org\/10.1172\/JCI117261.","journal-title":"J Clin Invest"},{"issue":"3part1","key":"797_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1212\/WNL.40.3_Part_1.495","volume":"40","author":"C Gellera","year":"1990","unstructured":"Gellera C, Uziel G, Rimoldi M, et al. Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology. 1990;40(3part1):495\u2013495. https:\/\/doi.org\/10.1212\/WNL.40.3_Part_1.495.","journal-title":"Neurology"},{"issue":"4","key":"797_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1542\/peds.89.4.730","volume":"89","author":"AM Remes","year":"1992","unstructured":"Remes AM, Hiltunen JK, Rantala H, Leisti J, Ruokonen A. Fumarase deficiency: two siblings with enlarged cerebral ventricles and polyhydramnios in utero. Pediatrics. 1992;89(4):730\u20134. https:\/\/doi.org\/10.1542\/peds.89.4.730.","journal-title":"Pediatrics"},{"issue":"9","key":"797_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/humu.21534","volume":"32","author":"C Ottolenghi","year":"2011","unstructured":"Ottolenghi C, Hubert L, Allanore Y, et al. Clinical and biochemical heterogeneity associated with fumarase deficiency. Hum Mutat. 2011;32(9):1046\u201352. https:\/\/doi.org\/10.1002\/humu.21534.","journal-title":"Hum Mutat"},{"issue":"1","key":"797_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2350-9-20","volume":"9","author":"JP Bayley","year":"2008","unstructured":"Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet. 2008;9(1):20. https:\/\/doi.org\/10.1186\/1471-2350-9-20.","journal-title":"BMC Med Genet"},{"issue":"4","key":"797_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ng849","volume":"30","author":"IPM Tomlinson","year":"2002","unstructured":"Tomlinson IPM, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406\u201310. https:\/\/doi.org\/10.1038\/ng849.","journal-title":"Nat Genet"},{"issue":"4","key":"797_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","volume":"13","author":"FH Menko","year":"2014","unstructured":"Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637\u201344. https:\/\/doi.org\/10.1007\/s10689-014-9735-2.","journal-title":"Fam Cancer"},{"issue":"6","key":"797_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cge.13014","volume":"92","author":"M Muller","year":"2017","unstructured":"Muller M, Ferlicot S, Guillaud-Bataille M, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French mutation carriers. Clin Genet. 2017;92(6):606\u201315. https:\/\/doi.org\/10.1111\/cge.13014.","journal-title":"Clin Genet"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-020-00214-9","volume":"8","author":"R Panarsky","year":"2020","unstructured":"Panarsky R, Crooks DR, Lane AN, et al. Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. Cancer Metab. 2020;8:7. https:\/\/doi.org\/10.1186\/s40170-020-00214-9.","journal-title":"Cancer Metab"},{"issue":"4","key":"797_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41374-017-0003-6","volume":"98","author":"IM Schaefer","year":"2018","unstructured":"Schaefer IM, Hornick JL, Bov\u00e9e JVMG. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Lab Invest. 2018;98(4):414\u201326. https:\/\/doi.org\/10.1038\/s41374-017-0003-6.","journal-title":"Lab Invest"},{"issue":"1","key":"797_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/biom10010143","volume":"10","author":"P Podkalicka","year":"2020","unstructured":"Podkalicka P, Mucha O, Kruczek S, et al. Synthetically lethal interactions of Heme Oxygenase-1 and fumarate hydratase genes. Biomolecules. 2020;10(1):143. https:\/\/doi.org\/10.3390\/biom10010143.","journal-title":"Biomolecules"},{"issue":"4","key":"797_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1042\/BST20150041","volume":"43","author":"IS Sandhu","year":"2015","unstructured":"Sandhu IS, Maksim NJ, Amouzougan EA, Gallion BW, Raviele ALJ, Ooi A. Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). Biochem Soc Trans. 2015;43(4):650\u20136. https:\/\/doi.org\/10.1042\/BST20150041.","journal-title":"Biochem Soc Trans"},{"issue":"664","key":"797_CR15","doi-asserted-by":"publisher","first-page":"eabc4436","DOI":"10.1126\/scisignal.abc4436","volume":"14","author":"DR Crooks","year":"2021","unstructured":"Crooks DR, Maio N, Lang M, et al. Mitochondrial DNA alterations underlie an irreversible shift to aerobic Glycolysis in fumarate hydratase-deficient renal cancer. Sci Signal. 2021;14(664):eabc4436. https:\/\/doi.org\/10.1126\/scisignal.abc4436.","journal-title":"Sci Signal"},{"issue":"10","key":"797_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","volume":"31","author":"MJ Merino","year":"2007","unstructured":"Merino MJ, Torres-Cabala C, Pinto P, Marston Linehan W. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31(10):1578. https:\/\/doi.org\/10.1097\/PAS.0b013e31804375b8.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"797_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ajcp\/aqac148","volume":"159","author":"V McMurtry","year":"2023","unstructured":"McMurtry V, Mahlow J, Coleman JF, et al. Morphologic characteristics and mutational analysis of fumarate hydratase deficient kidney and smooth muscle tumors. Am J Clin Pathol. 2023;159(2):164\u201371. https:\/\/doi.org\/10.1093\/ajcp\/aqac148.","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"797_CR18","doi-asserted-by":"publisher","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","volume":"99","author":"GR Clark","year":"2014","unstructured":"Clark GR, Sciacovelli M, Gaude E, et al. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metabolism. 2014;99(10):E2046\u201350. https:\/\/doi.org\/10.1210\/jc.2014-1659.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"9","key":"797_CR19","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","volume":"23","author":"LJ Castro-Vega","year":"2014","unstructured":"Castro-Vega LJ, Buffet A, De Cubas AA, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet. 2014;23(9):2440\u20136. https:\/\/doi.org\/10.1093\/hmg\/ddt639.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"797_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10689-011-9428-z","volume":"10","author":"HJ Lehtonen","year":"2011","unstructured":"Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer. 2011;10(2):397\u2013411. https:\/\/doi.org\/10.1007\/s10689-011-9428-z.","journal-title":"Fam Cancer"},{"issue":"SUPPL 1","key":"797_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41431-021-01026-1","volume":"30","author":"E Damaso","year":"2022","unstructured":"Damaso E, Heras ABS, Esteve Y, et al. Hereditary leiomyomatosis and renal cell carcinoma: identification and characterization of a new Spanish founder mutation in the FH gene. Eur J Hum Genet. 2022;30(SUPPL 1):401\u20132. https:\/\/doi.org\/10.1038\/s41431-021-01026-1.","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"797_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.urolonc.2021.07.026","volume":"39","author":"Y Yu","year":"2021","unstructured":"Yu Y, Zheng M, Zhu W, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): case series and review of the literature. Urol Oncol. 2021;39(11):791.e9-791.e16.","journal-title":"Urol Oncol"},{"issue":"3","key":"797_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3390\/genes14030744","volume":"14","author":"Y Shi","year":"2023","unstructured":"Shi Y, Xu Y, Wang C, et al. A missense mutation c.1132G\u2009>\u2009A in fumarate hydratase (FH) leads to hereditary leiomyomatosis and renal cell Cancer (HLRCC) syndrome and insights into clinical management in uterine leiomyomata. Genes. 2023;14(3):744. https:\/\/doi.org\/10.3390\/genes14030744.","journal-title":"Genes"},{"issue":"12","key":"797_CR24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1136\/jmg-2023-109328","volume":"60","author":"HH Pan","year":"2023","unstructured":"Pan HH, Ruan DD, Wu M, et al. Clinical phenotype and genetic function analysis of a rare family with hereditary leiomyomatosis and renal cell carcinoma complicated with Birt\u2013Hogg\u2013Dub\u00e9 syndrome. J Med Genet. 2023;60(12):1210\u20134. https:\/\/doi.org\/10.1136\/jmg-2023-109328.","journal-title":"J Med Genet"},{"issue":"1","key":"797_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10689-016-9922-4","volume":"16","author":"C Arenas Valencia","year":"2017","unstructured":"Arenas Valencia C, Rodr\u00edguez L\u00f3pez ML, Cardona Barreto AY, Garavito Rodr\u00edguez E, Arteaga D\u00edaz CE. Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family. Fam Cancer. 2017;16(1):117\u201322. https:\/\/doi.org\/10.1007\/s10689-016-9922-4.","journal-title":"Fam Cancer"},{"issue":"1","key":"797_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10689-011-9485-3","volume":"11","author":"VM Raymond","year":"2012","unstructured":"Raymond VM, Herron CM, Giordano TJ, Gruber SB. Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. Fam Cancer. 2012;11(1):115\u201321. https:\/\/doi.org\/10.1007\/s10689-011-9485-3.","journal-title":"Fam Cancer"},{"issue":"4","key":"797_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1525-1578(10)60574-0","volume":"7","author":"S ALAM N A, OLPIN","year":"2005","unstructured":"ALAM N A, OLPIN S, ROWAN A, et al. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn. 2005;7(4):437\u201343.","journal-title":"J Mol Diagn"},{"issue":"1","key":"797_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2230.2004.01675.x","volume":"30","author":"I CHAN","year":"2005","unstructured":"CHAN I, WONG T, MARTINEZ-MIR A, et al. Familial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer. Clin Exp Dermatol. 2005;30(1):75\u20138.","journal-title":"Clin Exp Dermatol"},{"key":"797_CR29","doi-asserted-by":"publisher","first-page":"686556","DOI":"10.3389\/fonc.2021.686556","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, Li L, Zhang Y, Zeng C. Hereditary leiomyomatosis and renal cell cancer: recent insights into mechanisms and systemic treatment. Front Oncol. 2021;11:686556. https:\/\/doi.org\/10.3389\/fonc.2021.686556.","journal-title":"Front Oncol"},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"906014","DOI":"10.3389\/fonc.2022.906014","volume":"12","author":"AK Lindner","year":"2022","unstructured":"Lindner AK, Tulchiner G, Seeber A, Siska PJ, Thurnher M, Pichler R. Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. Front Oncol. 2022;12:906014. https:\/\/doi.org\/10.3389\/fonc.2022.906014.","journal-title":"Front Oncol"},{"issue":"9","key":"797_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/14728222.2020.1804862","volume":"24","author":"P Kancherla","year":"2020","unstructured":"Kancherla P, Daneshvar M, Sager RA, Mollapour M, Bratslavsky G. Fumarate hydratase as a therapeutic target in renal cancer. Expert Opin Ther Targets. 2020;24(9):923\u201336. https:\/\/doi.org\/10.1080\/14728222.2020.1804862.","journal-title":"Expert Opin Ther Targets"},{"key":"797_CR32","doi-asserted-by":"publisher","unstructured":"Goswami PR, Singh G, Patel T, Dave R. The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates. Cureus. 16(4):e58470. https:\/\/doi.org\/10.7759\/cureus.58470","DOI":"10.7759\/cureus.58470"},{"issue":"1","key":"797_CR33","first-page":"236","volume":"13","author":"T SCHARNITZ","year":"2023","unstructured":"SCHARNITZ T, NAKAMURA M. The spectrum of clinical and genetic findings in hereditary leiomyomatosis and renal cell cancer (HLRCC) with relevance to patient outcomes: a retrospective study from a large academic tertiary referral center. Am J Cancer Res. 2023;13(1):236\u2013.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"797_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cncr.33997","volume":"128","author":"E LU","year":"2022","unstructured":"LU E, HATCHELL K E, NIELSEN S M, et al. Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. Cancer. 2022;128(4):675\u201384.","journal-title":"Cancer"},{"key":"797_CR35","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/PO.21.00263","volume":"5","author":"J KAMIHARA","year":"2021","unstructured":"KAMIHARA J, HORTON C, TIAN Y, et al. Different fumarate hydratase gene variants are associated with distinct Cancer phenotypes. Jco Precision Oncol. 2021;5:1568\u201378.","journal-title":"Jco Precision Oncol"},{"key":"797_CR36","doi-asserted-by":"crossref","unstructured":"S\u00e1NCHEZ-HERAS A B CASTILLEJOA, GARC\u00edA-D\u00edAZ JD et al. Hereditary leiomyomatosis and renal cell Cancer syndrome in spain: clinical and genetic characterization. Cancers (Basel), 2020, 12(11).","DOI":"10.3390\/cancers12113277"},{"issue":"4","key":"797_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10689-018-0076-4","volume":"17","author":"T BHOLA P","year":"2018","unstructured":"BHOLA P T, GILPIN C, SMITH A, et al. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC). Fam Cancer. 2018;17(4):615\u201320.","journal-title":"Fam Cancer"},{"key":"797_CR38","doi-asserted-by":"crossref","unstructured":"KOPP R, STRATTON K. GLOGOWSKI E, Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. J Urol, 2014, 1): e381.","DOI":"10.1016\/j.juro.2014.02.1070"},{"issue":"1","key":"797_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/PAS.0b013e31825ec16f","volume":"37","author":"J SANZ-ORTEGA","year":"2013","unstructured":"SANZ-ORTEGA J, VOCKE C, STRATTON P, et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol. 2013;37(1):74\u201380.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"797_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/jmg.2010.085068","volume":"48","author":"B Gardie","year":"2011","unstructured":"Gardie B, Remenieras A, Kattygnarath D, et al. Novel FH mutations in families with hereditary leiomyomatosis renal cell cancer (HLRCC) and in patients with isolated type 2 papillary renal cell carcinoma. J Med Genet. 2011;48(4):226. https:\/\/doi.org\/10.1136\/jmg.2010.085068.","journal-title":"J Med Genet"},{"issue":"1","key":"797_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1399-0004.2010.01486.x","volume":"79","author":"DL Smit","year":"2011","unstructured":"Smit DL, Mensenkamp AR, Badeloe S, et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet. 2011;79(1):49\u201359.","journal-title":"Clin Genet"},{"issue":"1","key":"797_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jmg.2005.033506","volume":"43","author":"MH Wei","year":"2006","unstructured":"Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43(1):18\u201327.","journal-title":"J Med Genet"},{"issue":"9","key":"797_CR43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1600-0625.2006.00470.x","volume":"15","author":"S Badeloe","year":"2006","unstructured":"Badeloe S, Van Geel M, Van Steensel MAM, et al. Diffuse and segmental variants of cutaneous leiomyomatosis: novel mutations in the fumarate hydratase gene and review of the literature. Exp Dermatol. 2006;15(9):735\u201341.","journal-title":"Exp Dermatol"},{"issue":"1","key":"797_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/376435","volume":"73","author":"JR Toro","year":"2003","unstructured":"Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73(1):95\u2013106.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"797_CR45","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/hmg\/ddg148","volume":"12","author":"NA Alam","year":"2003","unstructured":"Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet. 2003;12(11):1241\u201352.","journal-title":"Hum Mol Genet"},{"key":"797_CR46","doi-asserted-by":"crossref","unstructured":"Yu YF, Zheng MM, Zhu W, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): case series and review of the literature. Volume 39. Urologic Oncology-Seminars and Original Investigations; 2021. 11.","DOI":"10.1016\/j.urolonc.2021.07.026"},{"issue":"2","key":"797_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3343\/alm.2021.41.2.207","volume":"41","author":"JY Seo","year":"2021","unstructured":"Seo JY, Ahn JY, Keam B, et al. Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell Cancer syndrome in Korean patients. Annals Lab Med. 2021;41(2):207\u2013.","journal-title":"Annals Lab Med"},{"issue":"1","key":"797_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/humu.23900","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Walsh MF, Jairam S, et al. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Hum Mutat. 2020;41(1):103\u20139.","journal-title":"Hum Mutat"},{"issue":"12","key":"797_CR49","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/jclinpath-2020-206548","volume":"73","author":"M Furuya","year":"2020","unstructured":"Furuya M, Iribe Y, Nagashima Y, et al. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas. J Clin Pathol. 2020;73(12):819\u201325.","journal-title":"J Clin Pathol"},{"issue":"1","key":"797_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","volume":"44","author":"HD Lau","year":"2020","unstructured":"Lau HD, Chan E, Fan AC, et al. A clinicopathologic and molecular analysis of fumarate Hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol. 2020;44(1):98\u2013110.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"797_CR51","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","volume":"38","author":"YB Chen","year":"2014","unstructured":"Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and reenal cell carcinoma syndrome-associated renal Cancer recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38(5):627\u201337.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"797_CR52","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/gcc.20663","volume":"48","author":"TA Koski","year":"2009","unstructured":"Koski TA, Lehtonen HJ, Jee KJ, et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer. 2009;48(7):544\u201351.","journal-title":"Genes Chromosomes Cancer"},{"key":"797_CR53","doi-asserted-by":"publisher","first-page":"101963","DOI":"10.1016\/j.tranon.2024.101963","volume":"45","author":"L Wang","year":"2024","unstructured":"Wang L, Du R, Han L, Yang R, Li Y. A new missense mutation c.1240A\u2009>\u2009G in fumarate hydratase gene leads to uterine leiomyoma associated hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome in Chinese. Transl Oncol. 2024;45:101963. https:\/\/doi.org\/10.1016\/j.tranon.2024.101963.","journal-title":"Transl Oncol"},{"issue":"42","key":"797_CR54","doi-asserted-by":"publisher","first-page":"eabq8297","DOI":"10.1126\/sciadv.abq8297","volume":"8","author":"L Valcarcel-Jimenez","year":"2022","unstructured":"Valcarcel-Jimenez L, Rogerson C, Yong C, et al. HIRA loss transforms FH-deficient cells. Sci Adv. 2022;8(42):eabq8297. https:\/\/doi.org\/10.1126\/sciadv.abq8297.","journal-title":"Sci Adv"},{"issue":"7","key":"797_CR55","doi-asserted-by":"publisher","first-page":"112751","DOI":"10.1016\/j.celrep.2023.112751","volume":"42","author":"C Rogerson","year":"2023","unstructured":"Rogerson C, Sciacovelli M, Maddalena LA, et al. FOXA2 controls the anti-oxidant response in FH-deficient cells. Cell Rep. 2023;42(7):112751. https:\/\/doi.org\/10.1016\/j.celrep.2023.112751.","journal-title":"Cell Rep"},{"issue":"7363","key":"797_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature10363","volume":"477","author":"C Frezza","year":"2011","unstructured":"Frezza C, Zheng L, Folger O, et al. Haem Oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477(7363):225\u20138. https:\/\/doi.org\/10.1038\/nature10363.","journal-title":"Nature"},{"issue":"15","key":"797_CR57","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1128\/MCB.06160-11","volume":"32","author":"C Bardella","year":"2012","unstructured":"Bardella C, Olivero M, Lorenzato A, et al. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol. 2012;32(15):3081\u201394. https:\/\/doi.org\/10.1128\/MCB.06160-11.","journal-title":"Mol Cell Biol"},{"key":"797_CR58","doi-asserted-by":"publisher","unstructured":"Zyla RE, Hodgson A, BHOLA P T, GILPIN C, SMITH A et al. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC). Fam Cancer, 2018, 17(4): 615\u2013\u200920. J Clin Pathol. 2021;74(10):615\u2013619. https:\/\/doi.org\/10.1136\/jclinpath-2021-207830","DOI":"10.1136\/jclinpath-2021-207830"},{"key":"797_CR59","doi-asserted-by":"crossref","unstructured":"Sanchez-Heras AB, Damaso E, Castillejo A et al. Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome. Orphanet J Rare Dis, 2024, 19(1) (no pagination).","DOI":"10.1186\/s13023-024-03017-z"},{"issue":"12","key":"797_CR60","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/bjc.2012.483","volume":"107","author":"J Iqbal","year":"2012","unstructured":"Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005\u20139. https:\/\/doi.org\/10.1038\/bjc.2012.483.","journal-title":"Br J Cancer"},{"issue":"2","key":"797_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cncr.29041","volume":"121","author":"J Mersch","year":"2015","unstructured":"Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2):269\u201375. https:\/\/doi.org\/10.1002\/cncr.29041.","journal-title":"Cancer"},{"issue":"2","key":"797_CR62","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","volume":"11","author":"A Moran","year":"2012","unstructured":"Moran A, O\u2019Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11(2):235\u201342. https:\/\/doi.org\/10.1007\/s10689-011-9506-2.","journal-title":"Fam Cancer"},{"issue":"5","key":"797_CR63","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1055-9965.EPI-12-0195","volume":"22","author":"E Mocci","year":"2013","unstructured":"Mocci E, Milne RL, M\u00e9ndez-Villamil EY, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev. 2013;22(5):803\u201311. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-0195.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-025-00797-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-025-00797-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-025-00797-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:05:26Z","timestamp":1757264726000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-025-00797-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1186\/s40246-025-00797-8","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to participate, and consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}